COMMUNIQUÉS West-GlobeNewswire

Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development
06/02/2018
Allschwil, Switzerland - 06 February 2018 - Idorsia Ltd (SIX: IDIA) today announced its financial results as of December 31, 2017, which represent the business activities for the six and a half months since the demerger [...]
Targovax ASA: Invitation to fourth quarter and full year 2017 results presentation Thursday 15 February
06/02/2018
Oslo, Norway, 6 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its fourth quarter 2018 results on Thursday, 15 [...]
BCPhA Response to B.C. Government Retail Framework for Non-Medical Cannabis
06/02/2018
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- The BC Pharmacy Association (BCPhA) applauds the B.C. Government’s decision to make a clear distinction between non-medical cannabis and medical cannabis by [...]
Burcon NutraScience Announces Transfer of Listing to Nasdaq Capital Market
06/02/2018
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Burcon NutraScience Corporation (TSX: BU ) (NASDAQ: BUR ) (“Burcon” or the “Company”), a leader in natural product extraction, purification and isolation [...]
Correction from source: Aurora Spine Announces Upsizing of Private Placement
06/02/2018
CARLSBAD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (TSX-V: ASG ) ("Aurora Spine" or the "Company") is pleased to announce that, as a result of strong investor demand, it has increased the size [...]
BeiGene Announces Commercial Availability of VIDAZA® (Azacitidine for Injection) in China
06/02/2018
BEIJING, China, and CAMBRIDGE, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
Aurora Spine Announces Upsizing of Private Placement
05/02/2018
CARLSBAD, Calif., Feb. 05, 2018 (GLOBE NEWSWIRE) -- THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE [...]
Ari Kellen Acquires Common Shares of Vaxil Bio Ltd.
05/02/2018
TORONTO, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Ari Kellen announces that on January 26, 2018, he acquired (the " Acquisition ") by way of private placement ownership over 4,985,000 units (" Units ") of Vaxil Bio Ltd. (TSXV: [...]
BeiGene to Present Tislelizumab Data in Urothelial Carcinoma at the 2018 Genitourinary Cancers Symposium
05/02/2018
CAMBRIDGE, Mass. and BEIJING, China, Feb. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2017
05/02/2018
PORTLAND, Maine, Feb. 05, 2018 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC ) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and [...]
Results from Phase I Study of CB-839 in Combination with Everolimus or Cabozantinib in Patients with Renal Cell Carcinoma to be Presented at the 2018 American Society of Clinical Oncology Genitourinary Cancer Symposium
05/02/2018
-Overall response rate of 40% and 100% disease control rate in advanced clear cell renal cell carcinoma patients treated with CB-839 plus Cabozantinib -Randomized placebo controlled CANTATA Phase 2 trial of CB-839 in [...]
Mesa Labs Reports Third Quarter Results
05/02/2018
LAKEWOOD, Colo., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB ) (we, us, our, “Mesa” or the “Company”) today reported its results for the third quarter ended December 31, 2017. Revenues for [...]
Argos Obtains Option to License PD1 Checkpoint Inhibitors
05/02/2018
- Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, [...]
T2 Biosystems Announces CFO Transition
05/02/2018
LEXINGTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO ) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that [...]
Actinium Pharmaceuticals to Present at the BIO CEO & Investor Conference
05/02/2018
NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it will be attending and presenting at the BIO CEO & Investor [...]
Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results
05/02/2018
Manufacturing process change implemented with improved assay performance Verification and Validation (V&V) studies for blood grouping to resume MosaiQ SDS Microarray preparing to enter into formal V&V studies [...]
Ossur Hf : Interim Report Q4 2017 and Annual Report 2017
05/02/2018
Announcement no. 8/2018 5 February 2018 Highlights Sales in Q4 2017 amounted to USD 154 million, corresponding to 7% organic growth. Sales for FY 2017 amounted to USD 569 million, corresponding to 8% growth and 5% [...]
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/02/2018
MALVERN, Pa., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS ), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and [...]
Nuvectra™ Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
05/02/2018
PLANO, Texas, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR ), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 [...]

Pages